Cargando…
MAOI Antidepressants: Could They Be a Next-Generation ICB Therapy?
Autores principales: | Brown, James, Li, Bo, Yang, Lili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963899/ https://www.ncbi.nlm.nih.gov/pubmed/35359979 http://dx.doi.org/10.3389/fimmu.2022.853624 |
Ejemplares similares
-
Antidepressants: From MAOIs to SSRIs and more
por: Ramachandraih, Chaitra T., et al.
Publicado: (2011) -
Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects
por: Brown, James, et al.
Publicado: (2022) -
Use of MAOIs in severe treatment-resistant depression: back to the old school
por: Cookey, Jacob
Publicado: (2021) -
IPMA-D based on ICB 4 courseware
por: Hermarij, John
Publicado: (2017) -
Role of MAOI drugs as triggers of manic episodes in bipolar disorders: A case report and a narrative review
por: Olivier Mayorga, L., et al.
Publicado: (2022)